In contrast, Kase et al. observed significantly longer ESCC-free survival in patients with Fas-positive (versus Fas-negative) tumors, and in FasL-negative (versus FasL-positive) tumors [9]. This evidence concerns the gene FAS and esophageal squamous cell carcinoma.